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Toxoplasma gondii SAG1, GRA1, and GRA7 recombinant antigens may be regarded as tools for the detection
of T. gondii immunoglobulin G antibodies in persons with chronic and acute toxoplasmosis. GRA7 is more
correlated with acute toxoplasmosis. A combination of these antigens will increase the sensitivity of enzyme-
linked immunosorbent assays.
Laboratory diagnosis of Toxoplasma infection is usually
based on the detection of specific antibodies. The enzyme-
linked immunosorbent assay (ELISA) is one of the easiest tests
to perform, and many serological tests for the detection of
Toxoplasma gondii-specific immunoglobulin are commercially
available. Most of these commercial kits use a native parasite
antigen prepared from tachyzoites. The use of recombinant
antigens would allow better standardization of the tests and
reduce the costs of production. In spite of the potential advan-
tages of using recombinant antigens in serology tests, only a
limited number of studies have combined more than one an-
tigen in an ELISA (1, 5, 6).
In this study we have evaluated the diagnostic usefulness of
the SAG1, GRA1, and GRA7 T. gondii recombinant antigens.
We chose SAG1 because it is one of the most immunogenic T.
gondii antigens, GRA1 because it is a major secretory antigen
recognized in chronically Toxoplasma-infected humans, and
GRA7 because it gives a very strong antibody response in the
acute phase of infection. These antigens were obtained by the
method described previously (3). Production of the T. gondii
native antigen was based on the standard procedure, by freez-
ing and thawing tachyzoites obtained from a parasite (RH
strain) maintained in a mouse. Each antigen was used at a
concentration of 10 g per ml. We used two in-house immu-
noglobulin G (IgG) ELISAs: (i) an IgG ELISA (rec-ELISA)
performed with T. gondii recombinant antigens and (ii) an IgG
ELISA (nat-ELISA) performed with the T. gondii native anti-
gen. The ELISA was carried out as described previously (3).
Each serum was examined twice. Results were determined for
each serum by calculating the mean value of the optical density
(OD) reading for duplicate wells. A positive result was esti-
mated as any value higher than the average OD reading plus
three standard deviations (cutoff) obtained with 10 sera from
the negative control serum group. The cutoff values were as
follows: 0.976 for SAG1, 0.865 for GRA7, 0.669 for GRA1,
0.905 for a combination of three recombinant antigens, and
1.095 for the native antigen. The results of rec-ELISAs were
compared with those obtained from a group of sera examined
by (i) an IgG in-house indirect fluorescent-antibody assay
(IFA), which was performed according to the standard method
of Goldman (2) by using tachyzoites as a T. gondii antigen
(bioMe´rieux, Marcy l’Etoile, France), (ii) a commercial IgG
ELISA (com-ELISA) (Organon-Teknika, Boxtel, The Nether-
lands), and (iii) the TOXO-ISAGA PLUS IgA/IgM and
VIDAS TOXO IgG AVIDITY commercial tests (bio-
Me´rieux). All commercial tests were performed according to
the manufacturer’s procedures. Serum samples were obtained
from two diagnostic laboratories in Poland and one laboratory
in Denmark during routine diagnostic procedures. Written in-
formed consent was obtained from each study participant.
In the preliminary examination, pooled IFA-negative or
-positive sera with different titers were used. For further de-
tailed examination, the groups of sera from toxoplasmosis were
as follows: (i) group I, 206 sera from patients with indicative
infections acquired in the distant past (chronic toxoplasmosis),
examined for the first time with IgG IFA (n  82) or with IgG
com-ELISA (n  124), all IgM negative, and (ii) group II, 117
sera from patients suspected of having acute toxoplasmosis,
IgM and/or IgA positive, with low or high avidity. All sera were
reexamined with nat-ELISA, and only sera that were positive
in this test were used in the rec-ELISAs.
The results for pooled sera with different titers in the IFA
showed that OD readings were proportional to the tested se-
rum titers. With native SAG1 alone and a combination of
recombinant antigens, the OD readings obtained were similar
and much higher than those obtained with the GRA1 and
GRA7 antigens. An ELISA performed with the control Esch-
erichia coli antigen, produced and purified in the same way as
the recombinant antigens (3), showed an OD consistently be-
low 0.3, which demonstrates that possible contamination of the
* Corresponding author. Mailing address: Department of Tropical
Parasitology, Interfaculty Institute of Maritime and Tropical Medicine,
Medical University of Gdan´sk, 81-519 Gdynia, ul. Powstania Stycznio-
wego 9 b, Poland. Phone: 48-58-6998547. Fax: 48-58-6223354. E-mail:
pemyjak@immt.gdynia.pl.
1779
 
recombinant antigens with E. coli antigens does not influence
the rec-ELISA results. Only a few sera, which were low positive
by IFA, gave ODs that were higher with the E. coli antigen
than with GRA7 or GRA1, and these sera were considered to
be negative (data not shown).
Sera with no reactivity by the IFA or com-ELISA were also
negative in the rec-ELISA with each of the recombinant anti-
gens used. For sera from cases of chronic toxoplasmosis, the
sensitivity of antibody detection obtained with rec-ELISA was
higher when ranked by IFA or com-ELISA titers, reaching
78.0% for all sera with GRA7, 97.6% with the combination of
recombinant antigens in comparison to IFA, and from 68.7
(sera at titers of 1:100) to 100% (all sera at titers of 1:1,600)
in relation to the serum titers obtained by using com-ELISA
(Table 1).
In the group of sera from persons suspected of having acute
toxoplasmosis, sensitivity was high in subgroup A (the low or
borderline avidity), from 83.3% with GRA1 antigen to 98.6%
with SAG1 and 100% with the combination of recombinant
antigens. With the sera of subgroup B (high avidity), the results
obtained were identical to those for the combination of the
recombinant antigens and similar to those for SAG1 and
GRA1. In contrast, when GRA7 was used, the sensitivity was
significantly lower (only 68.9%, 2  16.1705, P0.001). All
sera from the control group, IgG and IgM negative, were also
negative with rec-ELISAs (Table 2).
The availability of large quantities of T. gondii recombinant
antigens will facilitate their use in diagnostic tests. We found
that a combination of three T. gondii antigens increased the
sensitivity of rec-ELISAs, especially with low-positive sera (Ta-
ble 1). Also, it has been our experience that the purity of the
recombinant proteins obtained from our E. coli expression
system and purification procedure is very important for the
accuracy of the rec-ELISA. Only a few sera that were low
positive by IFA gave ODs that were higher with control E. coli
antigen than with GRA1 and GRA7 antigens.
The best results reaching 100% were obtained with a com-
bination of the three recombinant antigens. These results are
consistent with the results of other investigators (1, 4) who
have found that combining complementary recombinant T.
gondii antigens together in the same immunoassay improves
the relative assay sensitivity.
Sera from patients with acute toxoplasmosis with low avidity
(group IIA) reacted with the GRA7 antigen with high sensi-
tivity (95.7%), whereas a much lower sensitivity (68.9%, P 
0.001) was obtained with sera from patients with previous
infection and sera with high avidity (group IIB). The sensitivity
obtained with GRA7 antigen was also lowest (78%) for group
TABLE 1. The results of the IgG rec-ELISAs obtained with T. gondii recombinant antigens compared with those of IgG IFA or
IgG com-ELISA (serum group I)
Test and titer
No. of
sera
examined
No. (%) of positive sera
GRA7 GRA1 SAG1 GRA7  GRA1 SAG1
IgG IFA
Negative (1:32) 20 0 (0) 0 (0) 0 (0) 0 (0)
1:128–1:256 (25–50 IU) 20 16 (80.0) 18 (90.0) 14 (70.0) 18 (90.0)
1:512–1:1,024 (100–200 IU) 26 18 (69.2) 20 (76.9) 24 (92.3) 26 (100)
1:2,048–1:8,192 (400–1,600 IU) 36 30 (83.3) 28 (77.8) 36 (100) 36 (100)
Total (1:128–1:8,192) 82 64 (78.0) 66 (80.5) 74 (90.2) 80 (97.6)
IgG ELISA
Negative (1:100) 41 0 (0)
1:100 16 11 (68.7)
1:200 24 21 (87.5)
1:400 31 29 (93.5)
1:800 25 24 (96.0)
1:1,600 28 28 (100)
Total (1:100–1:1,600) 124 113 (91.1)
TABLE 2. The results of the IgG rec-ELISAs obtained with T. gondii recombinant antigens with sera positive in IgM ISAGA and/or IgA
ISAGA (serum group II)a
Serum group
No. of
sera
examined
No. (%) of positive sera
GRA7 GRA1 SAG1 SAG1  GRA7
 GRA1
Subgroup A (IgM and/or IgA ISAGA positive, low or borderline avidity) 72 69 (95.9)b 60 (83.3) 71 (98.6) 72 (100)
Subgroup B (IgM and/or IgA ISAGA positive, high avidity) 45 31 (68.9)b 35 (77.8) 45 (100) 45 (100)
Total (IgM and/or IgA ISAGA positive, low or high avidity) 117 100 (85.5) 95 (81.2) 116 (99.1) 117 (100)
Negative control (IgG and IgM negative) 19 0 (0) 0 (0) 0 (0) 0 (0)
a ISAGA, immunosorbent-agglutination assay.
b 2  16.1705, P  0.001.
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I sera (chronic toxoplasmosis). The conclusion reached herein
is consistent with the results of Jacobs et al. (4) and Aubert et
al. (1), in which a similar sensitivity was obtained with GRA7
antigen in IgG rec-ELISA by using sera from acute and chronic
toxoplasmosis.
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